SECURITIES AND EXCHANGE COMMISSION
WASHINGTON,D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934
Date of Report (Date of earliest event reported): August 17, 2007
LIGAND PHARMACEUTICALS INCORPORATED
(Exact name of registrant as specified in its charter)
DELAWARE
(State or other jurisdiction of incorporation)
000-20720
(Commission File Number)
10275 SCIENCE CENTER DRIVE,
SAN DIEGO, CALIFORNIA
(Address of principal executive offices
(858) 550-7500
(Registrant's telephone number, including area code)
77-0160744
(I.R.S. Employer Identification No.)
92121-1117
(Zip Code)
Check the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant under any of the
following provisions (see General Instruction A.2. below):
|_| Written communications pursuant to Rule 425 under the Securities Act (17 CFR
230.425)
|_| Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|_| Pre-commencement communications pursuant to Rule 14d-2(b) under
the Exchange Act (17 CFR 240.14d-2(b))
|_| Pre-commencement communicationspursuant to Rule 13e-4(c) under the Exchange
Act (17 CFR 240.13e-4(c))
ITEM 5.02 DEPARTURE OF DIRECTORS OR PRINCIPAL OFFICERS; ELECTION OF DIRECTORS;
APPOINTMENT OF PRINCIPAL OFFICERS; COMPENSATORY ARRANGEMENTS OF
CERTAIN OFFICERS.
On August 17, 2007, Ligand Pharmaceuticals Incorporated ("Ligand")
entered into Change in Control Severance Agreements with each of the following
executive officers:
John L. Higgins President and Chief Executive Officer
Charles S. Berkman, J.D. Vice President,General Counsel
and Secretary
Zofia E. Dziewanowska, M.D., Ph.D. Vice President,Clinical Research
Syed Kazmi, Ph.D, M.B.A. Vice President,Business Development
Martin D. Meglasson, Ph.D. Vice President,Discovery Research
John Sharp, C.P.A. Vice President,Finance
and Chief Financial Officer
The form of Executive Officer Change in Control Severance Agreement is
attached to this Form 8-K as Exhibit 10.1 and incorporated herein by reference.
ITEM 9.01. FINANCIAL STATEMENTS AND EXHIBITS.
(c) EXHIBITS.
Exhibit
NUMBER DESCRIPTION OF EXHIBIT
10.1 Form of Executive Officer Change in Control
Severance Agreement.
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934,
the registrant has duly caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
LIGAND PHARMACEUTICALS INCORPORATED
Date : August 22, 2007 By: /s/Charles S. Berkman
Name: Charles S. Berkman
Title: Vice President, General Counsel & Secretary
EXHIBIT INDEX
Exhibit
NUMBER DESCRIPTION OF EXHIBIT
10.1 Form of Executive Officer Change in Control Severance Agreement.